{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:07:38Z","timestamp":1781125658334,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annder.2026.103479","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:02:57Z","timestamp":1773810177000},"page":"103479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gamma secretase inhibitor nirogacestat and secondary hidradenitis suppurativa: An expected on-target effect"],"prefix":"10.1016","volume":"153","author":[{"given":"M.","family":"D\u2019Agostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gerard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1925-1243","authenticated-orcid":false,"given":"D.","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-6633","authenticated-orcid":false,"given":"V.","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2026.103479_b0005","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2026.103479_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1684\/ejd.2025.4860","article-title":"Hidradenitis suppurativa: pathogenesis","volume":"35","author":"Villani","year":"2025","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2026.103479_b0015","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1111\/jdv.19544","article-title":"Hidradenitis suppurativa secondary to treatment with a gamma secretase inhibitor","volume":"38","author":"R\u00edos-Vi\u00f1uela","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2026.103479_b0020","first-page":"1","article-title":"Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication","volume":"57","author":"Frantz","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2026.103479_b0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jid.2017.09.051","article-title":"Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase","volume":"138","author":"O'Sullivan Coyne","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2026.103479_b0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-024-02002-x","article-title":"Nirogacestat: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.annder.2026.103479_b0035","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jid.2021.01.023","article-title":"Insights from \u03b3-secretase: functional genetics of hidradenitis suppurativa","volume":"141","author":"Vellaichamy","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2026.103479_b0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2025.05.042","article-title":"New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: a case report","volume":"63","author":"Gutierrez","year":"2025","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2026.103479_b0045","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2026.103479_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35965","article-title":"Top advances of the year: sarcoma","volume":"131","author":"Vierra","year":"2025","journal-title":"Cancer"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382600013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382600013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:44:57Z","timestamp":1781124297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196382600013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S015196382600013X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2026.103479","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gamma secretase inhibitor nirogacestat and secondary hidradenitis suppurativa: An expected on-target effect","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2026.103479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103479"}}